Akums Drugs & Pharmaceuticals Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q3 FY26 earnings call: what management guided on revenue, margins and order book.

Published 11 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹11.4K Cr

Q4 and near-term CDMO volume growth expected to remain strong with double-digit growth visible in Q4. The company expects steady volume growth to continue, with Q4 also showing strong double-digit volume traction, indicating near-term sustainability.

From Akums Drugs & Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

📊 Revenue & Sales Performance

→Q4 and near-term CDMO volume growth expected to remain strong with double-digit growth visible in Q4.
→FY '26: Zambia contract supplies expected to generate $25 million revenue in H1, with similar revenue expected in FY '27.
→FY '27 capex to continue in line with past trends, focused on capacity expansion to meet growing dosage form needs.
→European CDMO contract: Annual opportunity estimated at EUR35 million, with commercial supplies slated to start in FY '27 after registration in Europe.
→Domestic business volumes expected to align with industry growth from next fiscal year, after minimal price increases and HQ rationalizations.
→Management aiming for breakeven and turnaround in API business through portfolio diversification and entering regulated markets.
→Strategic capacity utilization peak anticipated around 55-60%, with buffer capacity to handle demand surges.
→Longer-term sustainability of volume growth is supported by broad-based client and therapy area expansion.

📈 Profitability & Margins

→The company expects steady volume growth to continue, with Q4 also showing strong double-digit volume traction, indicating near-term sustainability.
→Operating leverage benefits are anticipated as capacity utilization moves from current ~47% toward a peak of 55-60%, supporting margin expansion.
→Continued investment in capital expenditure will support growth in dosage forms where capacity is stretched.
→EBITDA margins in the domestic business may see further improvement due to high gross margins and fixed cost leverage.
→European CDMO supplies are expected to start by FY '28, adding to revenues and profits.
→Zambia contract supplies from Indian plants are expected in H1 FY '27, with $25 million revenue anticipated in both calendar years 2026 and 2027.
→API business losses are reducing due to portfolio rationalization and cost optimization, improving sequential performance but turnaround timing is uncertain.
→Overall, the company is committed to innovation, operational efficiency, and strategic partnerships to drive long-term value and growth.

See what Akums Drugs & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→The company has made a total capital expenditure (capex) of INR 165 crores in the first 9 months, with INR 57 crores invested in the latest quarter.
→Capex investments will continue steadily, aligned with business requirements, maintenance, and modernization efforts, following past trends.
→Buffer capacity is maintained to handle increased demand and sudden growth; peak capacity utilization is around 55-60%.
→Future capex will focus on serving dosage forms where current capacities are stretched.
→The company is actively evaluating multiple strategic acquisitions to complement existing business, but no binding deals yet.
→Investments are ongoing in technological upgrades and R&D to maintain and improve margin profile.
→Zambia contract execution includes facility erection and commissioning planned over two years, signaling future capital deployment.

💰 Fundraising & Capital Structure

→There is no specific mention of any immediate or planned new fundraising through debt or equity in the provided transcript.
→The company currently has a strong cash surplus of INR 1,573 crores and generated significant free cash flow (INR 944.5 crores).
→Sahil Maheshwari mentioned that they are actively evaluating multiple opportunities to complement their existing business but clarified that nothing is binding yet.
→The approach remains cautious, focusing on acquiring at the right price and ensuring incremental value to the business.
→No clear indications of upcoming fundraising rounds via debt or equity were discussed during this call.

See what Akums Drugs & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

→The European contract orderbook is significant, with discussions indicating an opportunity of approximately EUR 35 million annually.
→The supply of finished oral formulations from Plant 1 to Europe has already commenced in the current fiscal year.
→Injectable facilities and other plants are still ramping up, with utilization currently low (in the teens) and revenue contribution minimal, expected to increase notably in Q2 and Q3 of the next financial year.
→The company maintains a buffer capacity to accommodate demand spikes, with overall capacity utilization currently at about 47%, peaking at 55-60%.
→Growth drivers like new contracts (e.g., Zambian contracts) and increased demand suggest a substantial pipeline supporting future production.

Key Metrics

How does Akums Drugs & Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Akums Drugs & Pharmaceuticals Ltd

See full Pharmaceuticals & Biotechnology sector rankings

Price

₹750

Market Cap

₹11.4K Cr

P/E Ratio

37.5

Akums Drugs & Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹1.2K Cr, net profit ₹81 Cr.

Full financials →

What Akums Drugs's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
Mankind Pharma Ltd (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
Gland Pharma (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
Shilpa Medicare (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…

Compare:vs Sun Pharmaceutical Industries Ltd vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Akums Drugs & Pharmaceuticals Ltd Q3 FY26 results?

What is Akums Drugs & Pharmaceuticals Ltd share price analysis?

Akums Drugs & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 37.5 with a market cap of ₹11,436 Cr. Investors should review the full earnings analysis for detailed insights.

Is Akums Drugs & Pharmaceuticals Ltd planning capital expenditure?

The company has made a total capital expenditure (capex) of INR 165 crores in the first 9 months, with INR 57 crores invested in the latest quarter.

Keep Akums Drugs & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.